Introduction
Pancreatic cancer is the fourth leading cause of cancer-related death in the Western world and still has a rising incidence [
1]. Despite recent advances in systemic chemotherapy, long-term survival and cure are only possible with complete surgical resection [
2,
3]. In initially unresectable or borderline resectable cases, a complete tumor resection can be achieved after neoadjuvant chemotherapy or chemoradiation, especially after the introduction of the FOLFIRINOX regimen [
4‐
7]. Even in locally advanced cases with tumor infiltration into the mesenterico-portal axis (MPA), the celiac artery (CA), the hepatic arteries, or the superior mesenteric artery (SMA) as well as surrounding organs, an extended resection can be warranted in selected cases [
8‐
12]. To achieve complete oncologic resections of tumors in the pancreatic head, several surgical modifications to conventional partial pancreatoduodenectomy (PD) have been introduced in the last decade. The aim of these meanwhile standardized approaches is both an increase in safety as well as oncological radicality. These standardized approaches include “uncinate process first,” “artery first,” and the “triangle operation” which have been described recently [
13‐
17]. The combination of these techniques allows a systematic mesopancreatic dissection along the SMA together with the dissection alongside the CA, with a standardized radical clearance of potentially tumor-infiltrated lymphatic and neural tissue [
15,
18].
While a MPA resection with reconstruction is nowadays a standard procedure for tumors with a portal vein (PV) or superior mesenteric vein (SMV) infiltration, a cavernous transformation of the portal vein as a consequence of a complete portal vein occlusion still remains a dreaded challenge in pancreatic surgery [
11,
19‐
22]. In patients with a cavernous transformation, a pancreatic head resection can cause life-threatening intraoperative venous bleeding as well as a congestion of the intestine. Here, we provide a step-by-step instruction for pancreatic head resections with a “venous bypass graft first” approach for patients with cavernous transformation.
Discussion
Here, we describe an approach to render patients with a cavernous transformation of the portal vein due to occlusion of the splenic-mesenteric confluence by pancreatic head adenocarcinomas resectable in a controlled way avoiding fatal bleeding complications.
While tumor infiltration into the portal vein or superior mesenteric vein is no longer a contraindication for pancreatic head resection in pancreatic adenocarcinoma [
8,
10,
11,
18,
20,
21,
23,
24], the complete occlusion of the mesenterico-portal vein with a cavernous transformation remains a challenge. This challenge is both of technical and oncologic nature. Due to the varicose transformations of the collateral veins around the pancreas, the dissection of the pancreatic head can lead to massive bleeding. Controlling this bleeding by dissecting the veins may lead to an intolerable congestion of the intestines. Additionally, the hepatic perfusion can be limited when the venous collaterals are severed. All these intraoperative challenges can lead to additional postoperative morbidity and mortality. Oncologically, the challenge consists of large and advanced tumors; however, a R0 resection should remain the main objective of surgical resection [
2,
3]. The oncologic outcome in initially unresectable or borderline resectable patients can be improved by neoadjuvant therapy rendering more of these patients potentially resectable [
4,
25,
26]. Due to this, more patients are presented to the surgeons and new surgical approaches are warranted.
In the past years, many strategies were discussed to alleviate left-sided portal hypertension or mesenteric hypertension with cavernous transformation of the portal vein. Mesenteric venous shunts were initially developed to treat gastroesophageal variceal hemorrhage in patients with end-stage liver disease and portal hypertension. Now different versions of these shunts are also employed in pancreatic cancer surgery often developed from techniques used for extended pancreatic resections [
27,
28]. This can include temporary mesocaval shunts, which can be utilized to temporarily divert portal flow allowing for a safe portal dissection [
29,
30]. Also, the SMV can be directly sewn to the inferior vena cava (IVC) or an interposition graft can be utilized [
31]. For the interposition graft, it was described that autologous veins can be used. This includes for example the internal jugular vein to establish a temporary mesocaval shunt between the SMV and the IVC described by different groups [
32,
33]. An additional challenge in this case persists if the inferior mesenteric vein does not provide retrograde decompression of the left-sided portal hypertension. In these cases, another shunt from the left side with for example a splenorenal shunt is needed adding to the complexity of the procedure [
29]. All the approaches limit the blood flow through the liver during the time of the resection for up to several hours potentially leading even to portal vein thrombosis limiting their application.
Portal vein occlusion with extensive collateral vein formation is also a challenge in the surgery of patients with chronic pancreatitis for which different surgical techniques were developed [
34,
35]. The introduced methods specifically avoid dissection of the pancreas from the portal and superior mesenteric vein. In the multicenter randomized controlled ChroPac trial, it was concluded that in patients with a compression or occlusion of the portal vein system, a duodenum-preserving pancreatic head resection should be the procedure of choice instead of a partial pancreatoduodenectomy [
36]. Our approach could render these patients accessible to a partial pancreatoduodenectomy, which might be warranted as 5% of all patients in the trial had an incidental detection of pancreatic cancer [
36].
Our described approach provides continuous portal blood flow to the liver throughout the resection and reconstruction phase of the operation. In approaches that propose a mesocaval shunt, this is a limitation that cannot be avoided. Latest upon transection of the bile duct, the remaining blow flow via the cavernous transformed collateral veins is stopped. This leads inevitably to a prolonged liver ischemia/low perfusion which is of special importance as many patients already underwent multiple cycles of neoadjuvant hepatotoxic chemotherapy. Potential arterial clamping of the CA during the resection phase leads to a complete hepatic ischemia in approaches with a mesocaval shunt. However, rather than comparing our technique to alternative approaches which were highlighted, this article intends to provide an additional solution for a remaining challenge for pancreatic surgeons. Also, previously, Bachellier and colleagues suggested a similar surgical approach and commented on the advantages [
37]. In their manuscript, they reported that this procedure is safe as no postoperative mortality occurred. Often in this procedure also, an arterial resection was warranted. In 15 patients, the authors analyzed an overall mean survival of 17 months with a 3-year survival of 11% was reported [
37].
Surgical approaches which render unresectable patients amenable to radical local tumor resection are of high value for this small but existing subgroup of patients with pancreatic cancer suffering locally advanced but non-metastasized tumors. After neoadjuvant therapy, surgical resection becomes feasible in up to 60% of PDAC patients, which in the future could include more patients with cavernous transformed portal veins [
18,
38].
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.